secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K/A
Filed at:   2026-05-13T20:57:53+00:00
Accession:  0001501697-26-000051
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma amends 8-K to correct director nominee; shareholders approve 1.5M share increase in equity plan
--------------------------------------------------------------------------------

- Amended 8-K corrects nominee: Murray W. Stewart (not Michael S. Wyzga) elected as Class III director for 2029 term.
- Elected directors: Gary J. Bridger, Françoise De Craecker, Murray W. Stewart; each received >71M votes for, ~6.5M broker non-votes.
- Stockholders approved Second Amended and Restated 2017 Equity Incentive Plan, adding 1,500,000 shares (58.7M for, 17.7M against).
- Ratified PricewaterhouseCoopers as auditor for FY2026 (82.7M for, 69K against).
- Non-binding say-on-pay approved with 70.9M for, 5.4M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000051/0001501697-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000051/xfor-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001501697-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer